Recombinant Albumin

Product

Last mentioned: Mar 26, 2026

Timeline

  1. Q1 Guidance

    Precigen forecasts $18M+ revenue for Q1 2026, a massive sequential jump.

  2. Albumin Commercialization

    Dyadic and ProLiant Health launch recombinant albumin for global sales.

  3. FY 2025 Close

    Dyadic ends year with $8.6M cash; Paysign hits record $82M annual revenue.

  4. Papzimius Launch

    Precigen initiates commercial shipments of Papzimius for adult RRP.

Stories mentioning Recombinant Albumin 1

pharma Bullish

Commercial Inflection: Dyadic and Precigen Pivot to Product-Driven Revenue

Dyadic and Precigen have successfully transitioned from R&D-focused entities to commercial-stage biotechs, marked by the launch of recombinant albumin and Papzimius respectively. This shift is supported by a robust pharma services sector, as evidenced by Paysign’s record growth in patient affordability programs for top-tier manufacturers.

5 sources